-
01:34:36 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

CARA - Cara Therapeutics Inc

08/24/21 1:00 AM
Nasdaq : CARA
fda approval
Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
Regulatory News:This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210823005635/en/Vifor Pharma and Cara Therapeutics (Nasdaq:CARA) today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA™ (difelikefalin) for
RHEA-AI
very positive
08/23/21 3:41 PM
Nasdaq : CARA
fda approval
Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis Promotional launch of KORSUVA™ injection in the U.S. is expected in Q1 2022, with reimbursement in H1 2022 Company to host conference call today
RHEA-AI
very positive
04/29/21 7:00 AM
Nasdaq : CARA
clinical trial
Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
– Study did not meet Primary Endpoint of worst-itch NRS change from baseline at week 12 or Secondary Endpoint of 4-point responder analysis in the ITT patient population – Study achieved Primary Endpoint of worst-itch NRS change and Secondary Endpoint of 4-point responder analysis in pre-specified
RHEA-AI
neutral